| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -26.55 M USD | -28.20 M USD | -29.06 M USD | -28.36 M USD | -24.25 M USD | -16.93 M USD | -12.44 M USD | -11.32 M USD | -7.97 M USD | -5.90 M USD | -2.39 M USD | -183164 USD |
| Depreciation & Amortization | — | 1432 USD | 2668 USD | 2923 USD | 1492 USD | 844 USD | 893 USD | 1753 USD | 2632 USD | 1343 USD | 0 USD | — |
| Stock-Based Compensation | 10.84 M USD | 11.84 M USD | 6.62 M USD | 3.91 M USD | 1.45 M USD | 803261 USD | 715983 USD | 779701 USD | 986620 USD | 732151 USD | 486271 USD | 470185 USD |
| Capital Expenditures | — | — | — | — | 6938 USD | 1831 USD | — | — | 2126 USD | — | — | — |
| Cash Flow from Investing | -5.75 M USD | -5.00 M USD | — | — | -40.01 M USD | -1831 USD | — | — | -2126 USD | 255748 USD | — | — |
| Cash Flow from Financing | 33.30 M USD | 9.97 M USD | 13.83 M USD | — | 120.47 M USD | 22.90 M USD | 11.15 M USD | 17.30 M USD | 10.88 M USD | 5.26 M USD | 1.51 M USD | 1.68 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | -24.26 M USD | -16.93 M USD | — | — | -7.97 M USD | — | — | — |
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products. The company focuses on innovative therapies primarily in anti-infectives, oncology, adjunct cancer care, stem cell therapy, and unique prescription products. Its diverse pipeline includes candidates targeting serious medical conditions, reflecting a commitment to advancing treatments that address critical unmet needs in healthcare. With a strategic emphasis on critical care and oncology-related therapeutics, Citius plays a significant role in the pharmaceutical industry by aiming to improve patient outcomes through novel drug development. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals leverages its clinical expertise to progress products through late-stage development toward commercialization.